Skip to main content
NIHPA Author Manuscripts logoLink to NIHPA Author Manuscripts
. Author manuscript; available in PMC: 2008 Sep 10.
Published in final edited form as: Org Lett. 2006 Dec 21;8(26):6047–6049. doi: 10.1021/ol0624676

Synthesis of an Advanced Intermediate En Route to the Mitomycin Natural Products

Amie L Williams 1,§, Jayasree M Srinivasan 1,§, Jeffrey N Johnston 1,*
PMCID: PMC2533355  NIHMSID: NIHMS61663  PMID: 17165926

Abstract

An advanced intermediate in our planned synthesis of mitomycin C has been acquired in nine steps from tert-butyl glyoxylate. The aziridinyl pyrrolidine and quinone subunits are coupled regioselectively to arrive at an enamine that is prepared for C10 homologation.


The mitomycin natural products have attracted the attention of medicinal and synthetic chemists for nearly a half century.1,2 This interest results from several factors, including the continued clinical use of mitomycin C (1) for treatment of various forms of cancer. The unique pyrroloquinone backbone presents a high degree and density of oxidation, and this functional group array is the source of mitomycin C’s unique ability to crosslink DNA.3 Consequently, a substantial challenge for chemical synthesis is presented. Indeed, there have been many reports detailing synthetic efforts toward this class of natural products, and although interest has not waned with the passing of time, only two total syntheses of the title compound4 and two syntheses of another member of the class, mitomycin K (3)5, have been logged.

graphic file with name nihms61663f5.jpg

A successful synthesis, particularly one amenable to derivative formation, might further improve the therapeutic profile for this natural product class,6 and rejuvenate efforts to use contemporary biochemical techniques to similarly improve efficacy.

To achieve a high degree of convergency, our retrosynthesis disconnects the aziridinopyrrolidine and quinone across the central dihydropyrrole ring. On the basis of our previous studies of regioselective enamine additions to methoxy quinones,7 we expected the coupling of enamine 6 to quinone 7 to be regioselective for methoxy substitution at the bromomethoxy olefin.8 Construction of enamine 6 could arise from a cyclization of an amino alkyne via formal alkyne hydroamination. Convergency could again be served if an aziridine ring-forming reaction could be used that would also form the aziridine carbon-carbon bond. Hence, we began our studies by investigating the traditional methods for aziridine construction by carbon-carbon bond formation.9

Scheme 1 lists several general lines of investigation toward this end. Based on the work of O’Donnell10 and Miller,11 we anticipated that glycinyl Schiff base 8 might engage propargyl aldehyde 7 in an aldol reaction. The resulting β-hydroxy ester could be converted to the corresponding mesylate. In order to avoid competitive cyclization to the corresponding oxazoline,12 in situ trapping with mesyl chloride was necessary. Reductive amination then provided the desired aziridine in good overall yield. Unfortunately, the initial addition was minimally diastereoselective and favored the undesired trans-isomer.

Scheme 1.

Scheme 1

Approaches to the synthesis of cis-aziridine precursors to 6

The Darzens reaction13 using an azomethine electrophile provided a more direct route to the aziridine since it avoided the necessity to activate the hydroxy imine intermediate in eq 1 and reduce the imine functionality.14 The reaction of propargyl imine 10 under these conditions provided only trace amounts of aziridine, much less the desired cis-9. By activating the imine electrophile without resorting to a more robust protecting group at nitrogen, we examined the diphenylmethyl amine Schiff base of ethyl glyoxylate (11). Combination of the reactants at low temperature, followed by slow warming to room temperature, resulted in modest yields of the desired aziridine. Of greater significance is the high cis-diastereoselection observed in this transformation, a prerequisite for eventual formation of the aziridinopyrrolidine. Substitution of chloroacetonitrile for tert-butyl chloroacetate was also effective and cis-selective, but provided a greater amount of competing nitrile homocoupling.

Conversion of the cis-aziridinosuccinate 12 to enamine precursor 16 (Scheme 2) began with selective saponification of the ethyl ester using aqueous sodium hydroxide in ethanol (97%). Straightforward coupling of the carboxylic acid with commercial (S)-α-methyl benzylamine (98% ee) was achieved in 74% yield using DCC/HOBT to furnish diastereomeric cis-aziridines 14a/b. Selective reduction of tert-butyl ester 14 provided the corresponding aldehydes in good yield as judged by spectroscopic analysis of the crude reaction mixture. Careful chromatographic separation at this stage provided the diastereomeric cis-aziridines in pure form, however at the expense of chemical yield due to their instability. Subsequent alkynylation of the less polar aldehyde was effected using the Gilbert-Seyferth phosphonate reagent.15 In this manner, the terminal alkyne was produced in 85% yield from 14a. Red-Al reduction of the amide was similarly effective, and alkynyl amine 16a was obtained in 79% yield. Upon standing for one week, this amine crystallized and single crystals could be obtained by slow evaporation from dichloromethane. X-ray crystallographic analysis enabled assignment of the stereochemistry depicted in Scheme 2.

Scheme 2.

Scheme 2

Synthesis of alkynyl amine 16

* then separate diastereomers

An aminomercuration/coupling sequence was next evaluated with quinone 5 (Scheme 3). Enamine 6b was generated in situ by treatment of alkynylamine 16b16 with Hg(II),17 and this solution was added to quinone 5. The resulting deep blue solution was concentrated at 0 °C. Analysis of this crude reaction mixture by 1H NMR suggested selective and efficient production of a coupled product (see SI for details). However, successful purification of the putative enamine required cold column chromatography (ice water cooling). Using the bright color of the conjugated system as an indicator during this process, a product was isolated and kept at low temperature during NMR analysis. Notwithstanding, the material decomposed slowly with an approximate half-life of 1.5 days at −15 °C. The reactivity of this intermediate, manifested as instability during purification, is a feature we anticipated and desired as part of our synthesis strategy; notwithstanding, we sought to fully characterize it by spectroscopic means.

Scheme 3.

Scheme 3

Formation of the key enamine intermediate and subsequent alkylation to the mitomycin backbone

Immediate recognition of several features suggested its identity to be 4b. The aminobenzyl methine proton resonances are readily differentiated by chemical shift. The methine of the enamine is consistently deshielded to 4–5 ppm. The corresponding aziridine DPM-methine is further upfield at 3–4 ppm. HMBC, HMQC, and COSY experiments allowed assignment of all proton and carbon resonances. The coupling regiochemistry was identified by 3JCH between the enamine proton resonance (H9) and the quinone carbonyl carbon (C8) nearest the methoxy substituent. The latter was assigned indirectly by identification of the companion quinone carbonyl (C5) for which a 3JCH crosspeak could be observed from the quinone ring methyl subsituent. Consistent with our earlier observation, the methoxy group is preferentially substituted despite the electronic counter-influence of the distal methoxy. This behavior is consistent with rate-limiting addition in this nucleophilic vinylogous acyl substitution. The geometry of the newly formed enamine olefin was assigned by analogy to similar reactions we have investigated, all of which provide the E-olefin stereoisomer.7

In summary, we have arrived at an advanced intermediate (4) in our approach to the synthesis of the antitumor agent mitomycin C. This is accomplished in only nine steps from ethyl glyoxylate. The next significant step is homologation to install the C10 hydroxymethyl; the enamine character of 4, as well as the steric influence of the aziridine are perfectly suited to this task. Details on this front will be the subject of future reports.

Supplementary Material

si20061110_112. Supporting Information Available.

Preparative information and analytical data for all new compounds, as well as data (.cif) for structural determination of 16a.

Figure 1.

Figure 1

Retrosynthesis of mitomycin C

Acknowledgment

We are grateful to the National Institutes of Health (GM-63577) for support of this work. A.L.W. (IU) is the recipient of a Procter & Gamble graduate fellowship. J.N.J. (VU) is grateful for young investigator awards from Eli Lilly, Amgen, Astellas, and Boehringer-Ingelheim. We acknowledge the assistance provided by Dr. Doug Brown for the low temperature NMR experiments, and by Maren Pink for the X-ray structural determination of 16a.

References

  • 1.Isolation and initial structure determination. Webb JS, Cosulich DB, Mowat JH, Patrick JB, Broschard RW, Meyer WE, Williams RP, Wolf CF, Fulmor W, Pidacks C, Lancaster JE. J. Am. Chem. Soc. 1962;84:3185. Webb JS, Cosulich DB, Mowat JH, Patrick JB, Broschard RW, Meyer WE, Williams RP, Wolf CF, Fulmor W, Pidacks C, Lancaster JE. J. Am. Chem. Soc. 1962;84:3187. Tulinsky A. J. Am. Chem. Soc. 1962;84:3188.
  • 2.Selected recent leading references: Coleman RS, Felpin F-X, Chen W. J. Org. Chem. 2004;69:7309. doi: 10.1021/jo048924i. Vedejs E, Little J. J. Am. Chem. Soc. 2002;124:748. doi: 10.1021/ja0120835. Papaioannou N, Evans CA, Blank JT, Miller SJ. Org. Lett. 2001;3:2879. doi: 10.1021/ol016372+. Ziegler FE, Berlin MY, Lee K, Looker AR. Org. Lett. 2000;2:3619. doi: 10.1021/ol000245g. Ban Y, Nakajima S, Yoshida K, Mori M, Shibasaki M. Heterocycles. 1994;39:657. Lee J, Ha JD, Cha JK. J. Am. Chem. Soc. 1997;119:8127. Luly JR, Rapoport H. J. Org. Chem. 1984;49:1671.
  • 3.(a) Tomasz M. Chem. Biol. 1995;2:575. doi: 10.1016/1074-5521(95)90120-5. [DOI] [PubMed] [Google Scholar]; Sheldon PJ, Johnson DA, August PR, Liu H-W, Sherman DH. Dev. Ind. Microbiol. 1997;34:123. doi: 10.1128/jb.179.5.1796-1804.1997. [DOI] [PMC free article] [PubMed] [Google Scholar]; (b) Gargiulo D, Musser SS, Yang L, Fukuyama T, Tomasz M. J. Am. Chem. Soc. 1995;117:9388. [Google Scholar]; (c) Verweij J, Sparreboom A, Nooter K. Ch. 3. In: Pinedo HM, Longo DL, Chabner BA, editors. Cancer Chemotherapy and Biological Response Modifiers Annual. New York: Elsevier; 1999. [Google Scholar]; (d) Crown JP. Anti-Cancer Drugs. 1999;10:S19. doi: 10.1097/00001813-199911001-00004. [DOI] [PubMed] [Google Scholar]
  • 4.rac-1,2: Kishi Y, Fukuyama T. J. Nat. Prod. 1979;42:549. Fukuyama T, Yang L. J. Am. Chem. Soc. 1989;111:8303.
  • 5.rac-3: Benbow JW, Schulte GK, Danishefsky SJ. Angew. Chem. Int. Ed. Engl. 1992;31:915. See also Danishefsky SJ, Schkeryantz JM. Synlett. 1995:475. Wang Z, Jiminez LS. Tetrahedron Lett. 1996;37:6049.
  • 6.Kasai M, Kono M. Synlett. 1992:778. [Google Scholar]
  • 7.Cox AL, Johnston JN. Org. Lett. 2001;3:3695. doi: 10.1021/ol016625z. [DOI] [PubMed] [Google Scholar]
  • 8.(a) Theodorakis EA, Ling T, Rueden EJ, Poupon E, Kim SH. Strat. Tactics Org. Synth. 2004;5:111. [Google Scholar]; (b) Ling T, Poupon E, Rueden RJ, Kim SH, Theodorakis EA. J. Am. Chem. Soc. 2002;124:12261. doi: 10.1021/ja027517q. [DOI] [PubMed] [Google Scholar]; (c) Ling T, Poupon E, Rueden EJ, Theodorakis EA. Org. Lett. 2002;4:819. doi: 10.1021/ol025501z. [DOI] [PubMed] [Google Scholar]; (d) Stagliano KW, Lu Z, Emadi A, Harwood JS, Harwood CA. J. Org. Chem. 2004;69:5128. doi: 10.1021/jo049713g. [DOI] [PubMed] [Google Scholar]
  • 9.(a) Sweeney JB. Chem. Soc. Rev. 2002;31:247. doi: 10.1039/b006015l. [DOI] [PubMed] [Google Scholar]; (b) Graham MA, Thornton-Pett M, Rayner CM, Wadsworth AH. Chem. Commun. 2001:966. [Google Scholar]
  • 10.O’Donnell MJ. Ch. 10. In: Ojima I, editor. Catalytic Asymmetric Synthesis. 2nd ed. New York: Wiley-VCH; 2000. [Google Scholar]
  • 11.Gasparski CM, Miller MJ. Tetrahedron. 1991;47:5367. [Google Scholar]
  • 12.(a) Van Ornum SG, Bruendl MM, Cao H, Reddy M, Grubisha DS, Bennett DW, Cook JM. J. Org. Chem. 2000;65:1957. doi: 10.1021/jo9914014. [DOI] [PubMed] [Google Scholar]; (b) MacMillan JB, Molinski TF. Org. Lett. 2002;4:1883. doi: 10.1021/ol025876k. [DOI] [PubMed] [Google Scholar]
  • 13.Darzens G. Compt. Rend. 1904;139:1214. [Google Scholar]
  • 14.(a) Wartski L. J. Chem. Soc. Chem. Commun. 1977:602. [Google Scholar]; (b) Cainelli G, Panunzio M. Tetrahedron Lett. 1991;32:121. [Google Scholar]; (c) Vedejs E, Piotrowski DW, Tucci FC. J. Org. Chem. 2000;65:5498. doi: 10.1021/jo0001277. [DOI] [PubMed] [Google Scholar]
  • 15.(a) Seyferth D, Marmor RM, Hilbert PH. J. Org. Chem. 1971;37:1379. [Google Scholar]; (b) Gilbert JC, Weerasooriya U. J. Org. Chem. 1979;44:4997. [Google Scholar]; (c) Ohira S. Synth. Commun. 1989;19:561. [Google Scholar]; (d) Muller S, Liepold B, Roth GJ, Bestmann HJ. Synlett. 1996:521. [Google Scholar]
  • 16.The decision to use diastereomer cis-16b (as opposed to cis-16a) was rather arbitrary, determined by the available pure diastereomer at the time.
  • 17.(a) Barluenga J, Aznar F, Liz R, Rodes R. J. Chem. Soc. Perkin Trans 1. 1980:2732. [Google Scholar]; (b) Barluenga J, Aznar F, Liz R. Synthesis. 1984:304. [Google Scholar]; (c) Barluenga J, Aznar F, Liz R, Cabal MP. Synthesis. 1986:960. [Google Scholar]

Associated Data

This section collects any data citations, data availability statements, or supplementary materials included in this article.

Supplementary Materials

si20061110_112. Supporting Information Available.

Preparative information and analytical data for all new compounds, as well as data (.cif) for structural determination of 16a.

RESOURCES